

AGENDA
DEPARTMENT OF HEALTH
BOARD OF PHARMACY
FULL BOARD MEETING

CONFERENCE CALL

12:30 p.m., October 30, 2015

Call-in number: **888-670-3525**

Code: 5134896685

Board Members

Michele Weizer, PharmD, Chair, Boca Raton
Debra B. Glass, BPharm, Vice-Chair, Tallahassee
David Bisailon, Consumer Member, Bradenton
Goar Alvarez, PharmD, Cooper City
Leo "Lee" Fallon, BPharm, PhD, The Villages
Gavin Meshad, Consumer Member, Sarasota
Jeenu Philip, BPharm, Jacksonville
Mark Mikhael, PharmD, Orlando
Jeffrey J. Mesaros, PharmD, JD, Orlando

Board Staff

Allison Dudley, Executive Director
Emily Roach, Program Operations Administrator
Amber Greene, Regulatory Specialist III

Board Counsel

David Flynn, Assistant Attorney General

Meeting called to order at 12:31 p.m. by Dr. Michele Weizer.

Board member Gavin Meshad was absent. Dr. Jeffrey Mesaros joined the call later.

Board Counsel David Flynn explained the rule 64B16-28.831 had been rewritten to remove superfluous and repetitive language and to address some legal necessities. The new version makes the rule clearer, especially for people who are unfamiliar with it. He stated that the rule is substantially the same in meaning as what the board passed at its regular meeting Oct. 7, 2015.

Specifically, he said that subsection (3) Minimum Standards Before Refusing to Fill a Prescription was now more understandable.

Dr. Alvarez asked several questions to clarify that pharmacists don't have to do (a) and (b) if doing one satisfies the pharmacist's concerns about the prescription being valid.

Mr. Flynn said that once a pharmacist has resolved his or her concerns, it is no longer a refusal to fill issue, so the pharmacist can stop the validation steps and fill the prescription because it has been validated.

Mr. Flynn cited statistics provided on PDMP use that indicates pharmacists' rate of use is 89.66 percent. One of the steps allows pharmacists to use the PDMP instead of talking to the patient or prescriber.

Dr. Mesaros said he believed the nuances and organization of the language reflects the last conversations of the Controlled Substances Standards Committee and the full board.

Motion: by Dr. Mikhael, to approve the new language with two minor changes: striking "state" in the introduction and fixing the typo in (2)(b) to read "overheard." Motion carried.

Motion: by Dr. Weizer, to ratify that the economic impact motions passed by the board regarding the rule are still valid. Motion carried.

Motion: by Dr. Fallon, to adjourn at 1:03. Motion carried.